Long-term Enhanced ACO Design Model (LEAD)

Analysis updated November 9, 2026

Strategic questions for your team

Can our organization meet the 5,000 aligned Original Medicare beneficiary minimum (or the reduced 1,000-beneficiary threshold if ≥40% of our population qualifies as High Needs or ESRD) by January 1, 2027, and do we have at least 3,000 claims-based aligned beneficiaries in at least one base year to satisfy LEAD's baseline eligibility requirement?
Which risk-sharing option — Global Risk (100% upside/downside) or Professional Risk (50% upside/downside) — aligns with our organization's current financial reserves, loss-tolerance, and ability to post a financial guarantee sufficient to cover potential shared losses across a 10-year performance period running through December 31, 2036?
Given that LEAD withholds 3% of the financial benchmark as a Quality Withhold — with each of the five PY 2027 pay-for-performance measures (ACR, UAMCC, DAH, TFU, CAHPS) worth 0.60% each — what is our current performance on these measures relative to the 30th-percentile minimum threshold needed to earn any points, and do we have the care coordination infrastructure to avoid the 15% Initial Quality Score penalty triggered by a CI/SEP multiplier of 0.85 beginning in PY 2028?
Do we have or can we build the certified EHR technology (CEHRT) infrastructure necessary to submit dQM/eCQM data for Controlling High Blood Pressure (CBP) and Diabetes: Glycemic Status Assessment >9% (GSD) via FHIR API, Excel upload, or QRDA by PY 2027 to capture the optional 2.50 percentage-point quality score adjustment (1.25 points per measure), understanding these measures become mandatory pay-for-reporting in PY 2029 and pay-for-performance in PY 2031?
Are we operationally prepared to select and launch a Prevention and Quality Plan (PQP) intervention — choosing among the New Intervention, Existing Intervention, or RISE/CARA pathway — by the PY 2027 planning year deadline, recognizing that a fully executed PQP can earn up to 5 percentage points of quality score adjustment in PY 2027–2028 and up to 10 percentage points in PY 2029–2036, and that the selected pathway is locked for the model's duration absent CMS approval?
If we serve a high proportion of dually eligible or High Needs beneficiaries — defined as those requiring 24/7 provider access with EHR access, advanced care planning capability, and home-based care delivery — do we meet all three required care delivery capabilities that unlock lower beneficiary alignment minimums (e.g., 800 total / 500 claims-based in PY 2027), and have we modeled whether integrating these beneficiaries under a single ACO rather than a separate High Needs track produces better financial and clinical outcomes under LEAD's unified risk adjustment methodology?
Have we assessed the financial mechanics and cash flow implications of LEAD's prospective payment options — Primary Care Capitation (PCC), Total Care Capitation (TCC), and the Non-Primary Care Capitation (NPCC) — including the associated Medicare FFS fee reductions applied to Participant Providers enrolled in these mechanisms, and have we determined which capitation structure best supports our planned investments in team-based care and downstream value-based arrangements with Preferred Providers?
Is our organization eligible for and prepared to operationalize the CARA initiative — available exclusively to Global Risk Option ACOs — to establish episode-based risk arrangements with specialist Preferred Providers, including the RISE to Age in Place falls prevention episode (which satisfies PQP requirements and involves coordinated care teams of occupational therapists, physical therapists, registered nurses, and handypersons), and have we identified the specialist relationships and contractual frameworks needed to execute CARA participation by PY 2027?
Have we mapped our governance structure to LEAD's requirements — including a governing body with ≥75% voting control held by Participant Providers or Preferred Providers, a senior-level medical director who is a Participant Provider physically present at ACO locations, a designated compliance official reporting directly to the board, and either a Medicare beneficiary with voting rights on the governing body or a Beneficiary and Consumer Advisory Committee of at least 5 members meeting twice yearly — and can we document these structures before the application portal closes at 11:59 PM ET on May 17, 2026?
Have we evaluated the competitive positioning risk of remaining outside LEAD given that as of June 2025 only 45% of Original Medicare beneficiaries were aligned to the Shared Savings Program or ACO REACH, and CMS evidence shows non-ACO participants exhibit higher per-beneficiary spend, meaning LEAD participants who successfully capture shared savings and deploy Benefit Enhancements such as Part B cost-sharing support and the Part D premium buy-down (available by 2029) could attract beneficiaries away from non-participating practices in our market?
Given that CMS Administrator Dr. Oz has publicly stated ACOs are 'the best way to deliver health care' and that at least one ACO (Innovative Health ACO) has already been selected for LEAD model implementation, have we assessed whether CMS's favorable posture toward ACOs under the current administration strengthens the long-term policy durability of LEAD sufficiently to justify the 10-year commitment, and are we tracking early implementer experiences for performance benchmarks and operational lessons?
In light of expert analysis characterizing LEAD as a 'no-go' for certain health systems due to complexity and downside risk, have we conducted a rigorous internal assessment of whether our organization has the financial reserves, management bandwidth, and clinical infrastructure to absorb potential losses under Global Risk across a 10-year period, and have we stress-tested our business case against scenarios in which benchmark-setting, risk adjustment, or quality withhold mechanics underperform our projections?
Have we mapped the growing expert and industry concern that mandatory risk models may be forthcoming from CMS, and if so, does voluntary LEAD participation now serve as a strategic hedge — giving our organization a head start on capabilities (risk contracting, care management, data infrastructure) that would be required under a mandatory model — or does it represent premature exposure to downside risk that a mandatory model's design might handle differently?

Traps and concerns

Capitation Fee Reduction Reconciliation Lag
LEAD's prospective payment architecture — Primary Care Capitation (PCC), Total Care Capitation (TCC), and Non-Primary Care Capitation (NPCC) — requires CMS to apply fee reductions to FFS claims for all Participant Providers and Preferred Providers enrolled in capitated payment mechanisms. Because fee reductions are administered at the TIN/NPI level through CMS's claims adjustment system, any mid-year addition of Participant TINs or Preferred Providers creates a reconciliation gap: providers added after the performance year begins may continue billing at full FFS rates until CMS processes the amendment to the PY Participation Agreement. ACOs operating under Global Risk — liable for up to 100% of total losses relative to their established benchmark — absorb this exposure directly. During a 10-year model period without rebasing, even a single year of misaligned capitation enrollment for a large specialty group could materially distort the ACO's total cost of care accounting and produce unexpected shared loss liability at Final Financial Settlement.
Benchmark Adjustment Cap Asymmetry for MSSP Alumni
The benchmarking methodology applies differentiated caps to ACOs with prior Medicare Shared Savings Program (MSSP) participation within the previous two years: lower-spending ACOs are capped at 3% of risk-standardized USPCC for benchmark adjustments, while higher-spending ACOs are capped at 5%. This asymmetry creates a structural trap for lower-spending, efficiency-leading ACOs that have already reduced costs under MSSP — the very organizations LEAD is designed to retain. Their 3% cap constrains the benchmark adjustment headroom available to offset regional efficiency penalties and prior savings adjustments, compressing the 'wedge' between their benchmark and actual expenditures. Over a 10-year non-rebasing period, cumulative undercompensation relative to true cost trajectory could erode the financial case for continued participation, particularly for physician-led, independent, or rural ACOs operating on thin margins.
High Needs 40% Threshold Reclassification Mid-Model
ACOs qualifying for lower beneficiary alignment minimums — as low as 800 total aligned beneficiaries with 500 claims-based in PY 2027, rising to 1,600/1,000 by PY 2031 — must maintain a 40% High Needs and/or ESRD beneficiary threshold, verified by CMS prior to each performance year. Beneficiary category assignment has a layered priority rule: beneficiaries meeting both High Needs and Age & Disability (A&D) criteria are treated as High Needs, but beneficiaries meeting both High Needs and ESRD criteria are treated as ESRD — meaning ESRD beneficiaries count toward the 40% threshold but are benchmarked and risk-adjusted under ESRD rules, not High Needs rules. An ACO whose aligned population shifts — due to beneficiary death, disenrollment, or voluntary alignment changes — could fall below the 40% threshold mid-model and lose its alignment minimum exception, potentially triggering a minimum beneficiary shortfall that places the ACO in jeopardy of termination. This risk is amplified for small home-based primary care practices or hospice-adjacent organizations with high patient turnover.
CARA LPACA Amendment and Global Risk Lock-In
Participation in the CMS-Administered Risk Arrangements (CARA) initiative — which enables episode-based downstream risk arrangements with Preferred Provider specialists, including the RISE to Age in Place falls prevention episode — is exclusively available to ACOs in the Global Risk Option. ACOs must execute a separate LEAD Participation Agreement CARA Amendment (LPACA) to operationalize CARA. This creates a two-layer commitment trap: ACOs that select Global Risk to access CARA accept 100% downside liability on total Medicare Parts A and B spending, and simultaneously take on episode-level financial risk with specialists through negotiated CARA episode parameters. If a specialist Preferred Provider underperforms on a CARA episode — particularly for high-volume acute medical or procedural episodes — the ACO's Global Risk benchmark absorbs the blowback. Additionally, the RISE episode's coordinated care team (occupational therapists, physical therapists, registered nurses, and handypersons) represents a novel multi-disciplinary staffing model with no established actuarial baseline, creating pricing uncertainty in the episode-level financial settlement process.
eCQM/dQM Mandatory Transition Cliff at PY 2029
Controlling High Blood Pressure (CBP) and Diabetes: Glycemic Status Assessment Greater Than 9% (GSD) are optional reporting measures in PY 2027 and PY 2028 — earning ACOs up to 2.50 percentage points of quality score adjustment — but transition to mandatory pay-for-reporting in PY 2029 and PY 2030, and then mandatory pay-for-performance beginning PY 2031. The submission infrastructure requires either FHIR-based API integration using a CMS-provided LEAD Implementation Guide, HDR-Excel upload, or QRDA (acceptable only through PY 2028). ACOs that do not invest in certified EHR technology or FHIR API capability during the optional period face a hard compliance cliff at PY 2029: failure to report CBP and GSD means forfeiting 0.86 percentage points of the 3% quality withhold (the pay-for-reporting portion in PY 2029-2030), and by PY 2031, the full 0.86 percentage points shift to pay-for-performance risk — directly reducing quality withhold earn-back and triggering potential CI/SEP multiplier penalties of 0.85x applied to the entire Initial Quality Score. For rural, independent, and newly entering ACOs — LEAD's explicit recruitment targets — EHR interoperability investment timelines are frequently 18-36 months, making the PY 2029 deadline a structural operational hazard.
Substance Access BEI State-Law Compliance Exposure
The Substance Access Beneficiary Engagement Incentive (BEI) — allowing ACO participants to consult with beneficiaries about eligible hemp products — is available only in states where such products are legal, and all implementation and dispensing costs are borne entirely by the ACO participant with zero CMS reimbursement. CMS has indicated 'strict program integrity safeguards' will apply, but the specific compliance framework is not fully detailed in the RFA. ACOs operating across multi-state service areas face a patchwork legal environment: hemp product legality varies at the state level and can change legislatively mid-model. An ACO that launches a hemp consultation program in a state where it is currently legal, invests in staff training and protocols, and then faces a state-level legal reversal has no CMS indemnification and must immediately cease the BEI to avoid program integrity violations — which could trigger remedial action or termination provisions under Section XII of the RFA. The reputational and compliance cost of improperly administered Substance Access BEI activity, particularly given CMS's heightened program integrity focus under the current administration, could jeopardize the ACO's entire model participation status.
Convener ACO Provider Shuffling Three-Year Restriction
LEAD prohibits Participant TINs from joining a LEAD ACO affiliated with a particular convener if they participated in a different LEAD ACO affiliated with that same convener within the prior three performance years. This anti-gaming rule — designed to prevent selection gaming across a convener's portfolio of ACOs — creates a significant operational constraint for convener-affiliated organizations managing multiple ACO entities with overlapping provider panels. During a 10-year model period in which network composition inevitably evolves through practice acquisitions, mergers, or provider departures, a convener managing rural or independent practice ACOs may find that the three-year lookback period locks desirable Participant TINs out of optimal ACO placement. The restriction could force a convener to operate suboptimally-sized ACOs that struggle to meet the 5,000 minimum beneficiary alignment threshold — or the specialized High Needs thresholds of 800-1,600 beneficiaries — without access to otherwise eligible providers in their own network.